



October 26, 2022

Web Announcement 2930

## Updated Qualifying Clinical Trials (QCTs) Policy

- **Update to [Web Announcement 2665](#)**

Nevada submitted a State Plan Amendment (SPA) to add the Qualifying Clinical Trials (QCTs) benefit resulting from the Consolidated Appropriations Act (CAA) for 2021, clinic trial requirements. The SPA was approved by the Centers for Medicare & Medicaid Services (CMS) on May 3, 2022, retroactively to January 1, 2022.

This benefit allows Medicaid recipients coverage of routine patient costs for items and services furnished in connection with participation in a QCT.

Policy #15-1 Clinical Studies and Policy #15-2 Experimental Treatment sections have been removed from the Medicaid Services Manual (MSM) Chapter 1500 – Healthy Kids Program and relocated to MSM Chapter 600 – Physician Services, Attachment A, Policy #6-01, Qualifying Clinical Trials (QCTs).

Currently, there are no changes to reimbursement for services or existing prior authorization requirements.

- **New “Attestation Form on the Appropriateness of the Qualified Clinical Trial” (FA-110)**

A new form has been developed and provided by CMS to capture clinical trial attestations to confirm the trials are valid and approved through a system of peer review by the Secretary of the U.S. Department of Health and Human Services (DHHS).

The QCT principal investigator and the recipient’s healthcare provider must complete the Medicaid Attestation Form on the Appropriateness of the QCT (FA-110).

This form is available at <https://www.medicaid.nv.gov/providers/forms/forms.aspx>. The Medicaid Attestation Form must be submitted to the appropriate QIO-like vendor.